| dc.contributor.author | Waddingham, PH | en_US |
| dc.contributor.author | Chow, AW-C | en_US |
| dc.date.accessioned | 2019-07-15T14:24:36Z | |
| dc.date.available | 2019-02-11 | en_US |
| dc.date.issued | 2019-05 | en_US |
| dc.identifier.issn | 2050-0904 | en_US |
| dc.identifier.uri | https://qmro.qmul.ac.uk/xmlui/handle/123456789/58511 | |
| dc.description.abstract | All clinicians prescribing amiodarone require knowledge of the challenging diagnosis and management of amiodarone-induced pulmonary toxicity (APT), which is potentially fatal. APT should be considered early in all patients presenting with new respiratory symptoms and concurrent amiodarone therapy. Drug cessation and corticosteroid therapy can be highly effective once recognized. | en_US |
| dc.format.extent | 857 - 860 | en_US |
| dc.language | eng | en_US |
| dc.language.iso | en | en_US |
| dc.relation.ispartof | Clin Case Rep | en_US |
| dc.rights | Creative Commons Attribution‐NonCommercial License | |
| dc.title | Acute breathlessness with frank hemoptysis following catheter ablation for atrial fibrillation, a cause not so obvious. | en_US |
| dc.type | Article | |
| dc.rights.holder | © 2019 The Authors. | |
| dc.identifier.doi | 10.1002/ccr3.2082 | en_US |
| pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/31110703 | en_US |
| pubs.issue | 5 | en_US |
| pubs.notes | Not known | en_US |
| pubs.publication-status | Published online | en_US |
| pubs.volume | 7 | en_US |
| dcterms.dateAccepted | 2019-02-11 | en_US |
| rioxxterms.funder | Default funder | en_US |
| rioxxterms.identifier.project | Default project | en_US |
